HeraMED Partners with RMIT and DHCRC to Revolutionize AI-Driven Maternity Care

HeraMED Ltd. ( (AU:HMD) ) just unveiled an announcement.

HeraMED Limited has announced a partnership with RMIT University and the Digital Health Cooperative Research Centre to develop AI-driven maternity care solutions for culturally and linguistically diverse (CALD) women. The project aims to create predictive models for pre-term delivery risks linked to socio-economic factors, utilizing a diverse dataset to enhance clinical decision-making and personalized care. This collaboration aligns with HeraMED’s strategy to advance its HeraCARE platform and improve healthcare equity and access, potentially reducing biases in maternal-fetal diagnostics and care.

More about HeraMED Ltd.

HeraMED Limited is a leading company in women’s health technology and medical data, focusing on innovative solutions for maternal health. The company is known for its HeraCARE platform, which integrates advanced AI models to enhance healthcare delivery, particularly for culturally and linguistically diverse (CALD) women. HeraMED’s market focus includes leveraging data as an asset and commercializing AI-driven healthcare solutions.

YTD Price Performance: -40.0%

Average Trading Volume: 1,950,305

Technical Sentiment Signal: Sell

Current Market Cap: A$7.88M

Learn more about HMD stock on TipRanks’ Stock Analysis page.